St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
Peutz-Jeghers syndrome (PJS) is a genetic condition that causes non-cancerous growths to develop in the digestive system. It can also increase the risk of developing other types of cancer.
The growths, called hamartomatous polyps, usually grow in the small intestine. They can also grow in the:
Having PJS increases a person’s risk of developing the following types of cancers:
Other types of cancers can also happen in people with PJS.
Because PJS is inherited, it can be passed from parents to children. PJS often varies in how severe it is, even among people in the same family. Some people may have many polyps and may develop cancer at an early age. Others may only develop a few polyps and may not develop cancer.
People with PJS have an 85% risk of developing cancer by age 70. The risks for each type of cancer are shown in the table below:
Type of Cancer | Lifetime Risk |
---|---|
Breast cancer |
32–54% |
Colorectal cancer |
39% |
Pancreatic cancer |
11–36% |
Stomach cancer |
29% |
Ovarian cancer |
21% |
Lung cancer |
7–17% |
Cervical cancer |
10% |
People with PJS may have other medical issues. Not all people with PJS will have all of the symptoms or health conditions listed below.
The growth of polyps in the digestive system may cause:
Tumors of the ovaries and testicles may cause:
People with PJS often have small, dark-colored spots that look like freckles on parts of their skin. The spots usually appear during childhood. Most spots are on the lips, around and inside the mouth, near the eyes and nostrils, and around the anus. The spots may also occur on the hands and feet. They often fade as the person gets older.
Genes carry information telling cells in the body how to function. Peutz-Jeghers syndrome is caused by changes in a gene known as STK11. This gene helps tell cells how to grow and divide the right way.
Most people without PJS carry 2 working copies of the STK11 gene in their cells. The mother passes down 1 copy. The father passes down the other. Cells from people with PJS carry 1 working copy of the STK11 gene in their cells and 1 copy that is changed. This change causes the STK11 gene to not work right. When a gene change causes a disorder or disease, it is called a gene mutation.
About 50% (1 in 2) of children with PJS have inherited the STK11 gene mutation from a parent. The other 50% of children with PJS are the first people in their families to have the STK11 gene mutation. These children do not have a history of the condition in their families. In these cases, the change either happened in an egg or a sperm cell or it happened in one of the child’s cells during pregnancy. These children are the first in their families to have PJS.
No matter how they got the mutation, people with PJS have a 50% (1 in 2) chance of passing it on to their children.
Learn more about genetic counselors and understanding genetic risk.
A health care provider may suspect that your child has PJS after studying their medical and family cancer history.
This information helps the health care provider and the genetic counselor know if:
Your provider or genetics counselor may recommend STK11 genetic testing if they suspect PJS.
Learn more about types of genetic testing.
A blood sample is sent to a genetic testing lab. The lab runs genetic tests that looks for changes in the STK11 gene.
If your child has an STK11 mutation, the genetic counselor will work with your family to:
Parents may choose to do prenatal testing to find out if a pregnancy is affected with a known STK11 mutation. Testing may take place either before pregnancy occurs or during pregnancy.
You should work with a genetic counselor to review the pros and cons of the test. The genetic counselor can also help you prepare for the test results.
Testing before pregnancy is called preimplantation genetic testing (PGT). This special type of genetic testing is done along with in vitro fertilization (IVF). PGT tests embryos for a known STK11 mutation before a provider places the embryo into the uterus.
Testing during pregnancy can help providers see if a pregnancy has a known STK11 mutation. A doctor gathers cells from the pregnancy in 1 of 2 ways:
After tissue collection, the lab checks the sample for the STK11 mutation. Both tests carry minor risks. Discuss risks with an experienced health care provider or a genetic counselor.
Take time to think carefully about the benefits and risks of genetic testing. Speak with a genetic counselor before testing. If you decide to get tested, talk with your health care provider or a genetic counselor about your results so you can understand what they mean.
Sometimes, children or adults with PJS feel sad, anxious, or angry after getting their test results. Parents may feel guilty if they pass the STK11 gene mutation to 1 or more of their children. People with a STK11 gene mutation may also have trouble getting disability or life insurance.
Read more about genetic discrimination.
Children with PJS need regular screenings to detect cancer as early as possible. Get cancer screening in a center that has experience taking care of people with PJS.
All people with this condition should be screened. The goal of screening is to find and treat growths early for the best outcome. Talk about the benefits and risks of cancer screening with a doctor who knows the condition well.
The following guidelines for cancer screening in children and young adults with PJS are recommended:
Girls begin screening at age 25 or 5–10 years before the earliest diagnosis of breast cancer in the family, whichever is earlier. This screening includes the following:
MRI of the pancreas and bile ducts begins at age 30 and is repeated every 1–2 years. An endoscopic ultrasound combining endoscopy and ultrasound to let the health care provider see the digestive tract may be done instead of MR imaging.
A testicular exam is used to observe enlargement, masses, or evidence of feminizing changes, beginning at the age of diagnosis.
Suggested screenings may change over time as doctors learn more about PJS. Talk about all screening options with your care team. Because PJS is a complex condition, seek out an experienced doctor for your child. Yearly physical exams should be done by a health care provider who knows PJS well.
People of any age with PJS have a higher risk of cancer. It is important to monitor children’s health and help them adopt healthy habits. They need to have regular physical checkups and screenings. That way, the care team can find cancer early at the most treatable stage.
People with PJS should watch for signs or symptoms that could signal cancer, such as:
It is important to seek medical help if anything unusual appears.
Habits that will help you maintain a healthy lifestyle include:
The St. Jude Cancer Predisposition Program is dedicated to diagnosing and screening children with a genetic predisposition for cancer. Our program offers the best clinical care possible. We engage in cutting-edge research to gain more information about genetic disorders and cancer, and to improve the care and treatment for patients who are affected by these conditions. Learn more about the Division of Cancer Predisposition at St. Jude.
Our genetic counselors, clinicians, genetics nurse practitioners, and research assistants work together to provide patients with:
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults who have cancers associated with PJS.
Study goal:
To learn more about participants beliefs, attitudes, and questions about gene therapy to help make web-based resources to share information. This could help patients make treatment decisions.
Age:
18 to 35 years old with rare genetic diseases
Study goal:
The main goal of this study is to learn more about the reasons childhood tumors form and how to treat them better.
Study goal:
To provide a high-quality repository of tumor and normal samples to facilitate translational research performed by St Jude faculty and their collaborators
Study goal:
1) Test each patient for hundreds of gene variations that might be important for drug use. All of the gene test results will be in the research laboratory, but as time goes on, the study will evaluate scientific evidence and selectively move test results for a few genes into the medical record if the evidence strongly shows that the result can help in better prescribing of drugs for patients; 2) Estimate how often pharmacogenetic test results are moved from research tests into a patient’s medical record; 3) Use methods to choose which of these tests should be put in the medical record; 4) Use computer-based tools in the electronic medical record to help doctors use gene test results when prescribing drugs; 5) Share feelings and concerns of patients and their families about gene test information being put in their medical record.
Study goal:
The main purpose of this trial is to learn about the genetic causes of cancer.
Age:
Younger than 50 years old
Study goal:
To collect data about how Friedreich’s ataxia progresses over time and affects the daily life of patients.
Age:
Any
Study goal:
To find out how much patients with hemophilia B, their caregivers, and health care workers know about gene therapy for this disease, and how they feel about gene therapy. This will help us better educate patients and caregivers about gene therapy for hemophilia B.
Age:
12 years and older
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334
If you have questions about the Genetic Predisposition Clinic and care for PJS, email our team at GPTeam@stjude.org.